Interface Biologics has announced that its licensing partner, AngioDynamics, has obtained US Food and Drug Administration (FDA) clearance for use of BioFlo peripherally inserted central catheter (PICC) with Endexo technology.
Angiodynamics said that, following the acquisition of Navilyst Medical earlier in 2012, it has gained the license to incorporate Interface's Endexo technology in its PICC, ports and dialysis catheter products.
The self-locating bio-medical polymer, Endexo, forms a passivating surface to reduce platelet adhesion, protein adsorption and thrombus formation on medical devices.
The BioFlo PICC with Endexo technology has 87% less thrombus accumulation on its surface on average compared to commonly used PICCs, as demonstrated in in-vitro blood loop model test anaylsis.
In addition, side-by-side in vivo test results show substantially equivalent thromboresistant characteristics as a heparin coated vascular access catheter, according to the company.
AngioDynamics president and CEO Joseph DeVivo said the technology shows promise in decreasing the accumulation of catheter-related thrombus without incorporation of coated or impregnated technologies.
Interface Biologics president and CEO Tom Reeves said; "The launch of BioFlo PICC with Endexo Technology represents the first FDA clearance of a medical device that utilizes our Endexo Technology - a significant milestone for IBI and evidence of our continued commercial traction."
AngioDynamics plans to launch the CE-marked BioFlo PICC in the US within the next 30 days.